Answers are grounded in this paper and cite their sources.
Background: Sickle cell disease patients have a tendency for vaso-occlusive attacks involving their bones.Osteonecrosis results in infarction of the articular surfaces and heads of long bones, leading to chronic joint pain, significant interference in functioning and quality of life.Intra-articular Botox injection is safe andreduces chronic pain while patients' mobility. Objective:The study aimed to evaluate the symptomatic change and its duration after intra-articular Botox injection, in sickle cell disease patients with chronic pain.Methods: Sickle cell disease patients with chronic joint pain observed at Salmaniya medical complex were included.Patients were injected with Botox intra-articularly and followed up for a year.Symptomatic parameters were assessed at every follow-up, raw data collected was entered into Microsoft Excel spreadsheet were the numerical variables analyzed and graphs were created.Results: Forty-eight sickle cell disease patients were included.Post the intra-articular injection at 3 months, the level of pain according to, Numerical rating scale (NRS) reduced by 44.6% (p-value <0.005) and 27.8% (p-value < 0.001) at 6 months and 9.54% (p-value <0.01) at 1 year, and significant improvement of other parameters. Conclusion:Intra-articular BoNT/ A injection provides an alternative treatment in sickle disease patients with good results in reduction of pain, improved physical function, mood, and sleep pattern lasting at least 6 months.Although a small scale study, the results suggest that BoNT/ A is an effective and safe treatment.
No takes yet. Share an insight, caveat, or question.
A 2020 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: